Different studies have found that FANCE mutations in breast cancer [39], sarcoma [40], colorectal cancer [60], gastric cancer [38] and esophageal cancer [61], but its impact on the prognosis of these malignancies has not been reported. Here, FANCE is linked to breast carcinoma.